{"preliminary_commentary":{"by_channel":{"x_thread":112,"podcast":22,"youtube":12,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00297895\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T02:31:38.799Z","note":"Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.","passages_read":null,"text":"The commentary discusses MSLT-II in the context of sentinel-node-positive melanoma, including the choice between completion lymph node dissection and active surveillance with nodal ultrasound, and the broader role of lymph node surgery. Discussion also covers how the trial may inform clinical management and whether changing practice means abandoning completion dissection. A speaker raises the question of how long randomized-trial results take to be adopted, while other commentary focuses on the trial’s relevance to less extensive surgery."},"name":"MSLT-II","nct_id":"NCT00297895","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mslt-ii-nct00297895. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Ultrasound observation + delayed CLND if recurrence detected","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"CLND","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Institutes of Health (NIH)","National Cancer Institute (NCI)"],"completion_date":{"date":"2019-09-30","type":"ACTUAL"},"conditions":["Melanoma"],"enrollment":{"count":1939,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Completion Lymphadenectomy","otherNames":[],"type":"PROCEDURE"},{"name":"Monitoring with nodal ultrasound","otherNames":[],"type":"PROCEDURE"}],"last_update":"2022-05-13","lead_sponsor":"Saint John's Cancer Institute","official_title":"A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node","overall_status":"COMPLETED","phases":["NA"],"primary_completion_date":{"date":"2019-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Melanoma-specific survival. This is defined as the time between the date of a subject's randomization (or date of CLND for those randomized to the CLND arm) and the date of death due to melanoma. Subjects are followed until death or 10yrs.","timeFrame":"10 years"}],"references":[{"citation":"Multicenter Selective Lymphadenectomy Trials Study Group; Crystal JS, Thompson JF, Hyngstrom J, Caraco C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves RI, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, O'Donoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningen L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA Surg. 2022 Sep 1;157(9):835-842. doi: 10.1001/jamasurg.2022.2055.","pmid":"35921122","type":"DERIVED"},{"citation":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.","pmid":"28591523","type":"DERIVED"}],"start_date":{"date":"2004-09-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Multicenter Selective Lymphadenectomy Trial II (MSLT-II)","url":"https://clinicaltrials.gov/study/NCT00297895"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mslt-ii-nct00297895"}